Locations:
Abu Dhabi|Canada|Florida|London|Nevada|Ohio|
Gray gradientGray gradient
Cleveland Clinic icon
Consult QD logo
Search IconSearch

Tag: Lp(a)

Lp(a) particles floating among red blood cells

Lepodisiran’s Large, Durable Lp(a) Reductions in Phase 2 Trial Boost Anticipation of Phase 3 Results

Small interfering RNA lowered lipoprotein(a) by 94% during six-month follow-up after a single dose

angiogram showing microvascular disease

Bringing More Options to Bear in CAD – Part 2: Meeting Needs of Special Patient Populations

Resourceful approaches to the care of patients with microvascular disease and elevated Lp(a)

19-HVI-1792159; Steven Nissen, M.D., M.A.C.C.; Mike Viars

Lipoprotein(a): Progress on One of the Last Untreatable Frontiers of Cardiovascular Risk

It's time to increase testing for this major cardiovascular risk factor in advance of new therapies

Lipoproteins

Novel siRNA Reduces Lipoprotein(a) by More Than 90% for 48 Weeks

Undetectable levels achieved for nearly nine months in phase 1 trial

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

22-HVI-2769711_lipoprotein(a)_650x450

Novel siRNA Therapy Lowers Elevated Plasma Lipoprotein(a) in Phase 1 APOLLO Trial

Targeted mRNA blocking could be first effective approach specific to this cardiovascular risk factor

lipoprotein(a) particle

Elevated Lipoprotein(a): Is a Long-Sought Treatment Finally on the Way?

New phase 2 data boost hopes for phase 3 Lp(a) HORIZON trial

18-HRT-5855-AHA-650×450

AHA 2018 Essentials: Dr. Steve Nissen on What Mattered Most (Video)

Cholesterol guideline, vitamin D, REDUCE-IT and lipoprotein(a)

BackPage 1 of 1Next

Advertisement

Ad